LILLY (ELI) & COMPANY - FDA Approves EVISTA to Reduce Risk of Breast Cancer.

PR Newswire UK Disclose, September, 2007

 
For Release: September 14, 2007 
 
Refer to: Sharon Corbitt 
 
Office: (317) 277-1574 
 
Mobile: (317) 997-1206 
 
E-mail: corbittsd@lilly.com 
 
FDA Approves Lilly's Osteoporosis Drug EVISTAA[R] (raloxifene HCl) to Reduce The 
Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women 
 
First treatment approved to reduce invasive breast cancer risk 
 
in postmenopausal women with osteoporosis 
 
INDIANAPOLIS - September 14, 2007 - Today, Eli Lilly and Company (NYSE: LLY) 
announced that the U.S. Food and Drug Administration (FDA) has approved its 
osteoporosis drug EVISTAA[R] (raloxifene HCl) for a new use to reduce the risk of 
invasive breast cancer in two populations: postmenopausal women with 
osteoporosis and postmenopausal women at high risk for invasive...

            
        
    
    	    
                
                
	

		

					 
            Read the rest of this article with a Free Trial at HighBeam Research.
        				
 

    		            
	
                Premium Content Partnership | 
                	HighBeam Research provides an in-depth online archive library of reference works.